A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Guselkumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms Discover 2
- Sponsors Janssen Research & Development
- 08 Aug 2017 Planned End Date changed from 21 Oct 2021 to 20 Oct 2021.
- 08 Aug 2017 Status changed from not yet recruiting to recruiting.
- 11 Jul 2017 Planned end date changed from 27 Dec 2021 to 21 Oct 2021.